Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Struggling with Staying Informed? In the fast-paced world of diagnostic medicine, staying updated with the latest legal, compliance, regulatory, and industry insights is crucial. Yet, finding reliable and comprehensive information can be overwhelming and time-consuming.
Lab Industry Advisor to the Rescue! Lab Industry Advisor provides comprehensive, up-to-date insights and analyses tailored to your needs. With expert commentary and actionable advice, you’ll stay ahead of the curve. No more sifting through endless sources—everything you need is right here!
Start your free trial today and see how Lab Industry Advisor can transform your approach. Get instant access to invaluable resources designed to keep you informed and competitive. Explore detailed reports, in-depth articles, and exclusive industry insights that help you make better decisions faster. Choose from three subscription levels tailored to fit your needs: Essential, Premium, and Elite.
![Essential](https://www.g2intelligence.com/wp-content/uploads/2023/11/Essential.png)
![62934_G2_Subscription Website Images_JL V1](https://www.g2intelligence.com/wp-content/uploads/2023/11/62934_G2_Subscription-Website-Images_JL-V1.png)
![Special-Report](https://www.g2intelligence.com/wp-content/uploads/2023/11/Special-Report.png)
![62934_G2_Subscription Website Images_JL V12](https://www.g2intelligence.com/wp-content/uploads/2023/11/62934_G2_Subscription-Website-Images_JL-V12.png)
![Special-Analysis](https://www.g2intelligence.com/wp-content/uploads/2023/11/Special-Analysis.png)
![Elite](https://www.g2intelligence.com/wp-content/uploads/2023/11/Elite.png)
Additional Business Intelligence Offerings
Lab Industry Advisor Subscriptions Include
![paper_magnifing_glass_512](https://www.g2intelligence.com/wp-content/uploads/2023/11/paper_magnifing_glass_512.png)
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
FDA and CMS Announce Joint Task Force Focusing on LDT Regulation
By Kelly A. Briganti, Editorial Director, G2 Intelligence Asserting that the agencies' regulatory roles are not duplicative, the U.S. Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) announced formation of a joint task...
Investigators Use Cell Phone Records to Help Prosecute Fraud
By Christopher P. Young, Editor, G2 Compliance Advisor Investigators used cell phone location data in over 800 instances to prove that a physician was not present at El Centro Clinic at the time certain tests were administered, as is required by Medicare...
CDC Says 'Steady' Progress Made in Electronic Reporting of Lab Results
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies National implementation of electronic laboratory reporting (ELR) continues to increase, according to a progress report published April 3 in Morbidity and Mortality Weekly Report. The authors...
Rosetta Genomics Closes Deal to Acquire PersonalizeDx
By Ron Shinkman, Editor, Laboratory Industry Report New Jersey-based Rosetta Genomics has closed a deal to acquire CynoGen, Inc., which does business as PersonalizeDx, for $3.9 million in cash and stock. Rosetta acquired PersonalizeDx from California-based Prelude...
Expedited FDA Approval Process Begins for Diagnostic Devices Addressing Unmet Needs
By Kelly A. Briganti, Editorial Director, G2 Intelligence Starting April 15, the FDA will begin implementing an expedited approval process for devices subject to premarket approval or de novo requests that can satisfy unmet needs for life-threatening or...